Navigation Links
Weill Cornell receives funding to study creation of new elder abuse center
Date:5/6/2008

s and Gerontology, director of the Center for Aging Research and Clinical Care, and the Irene F. and I. Roy Psaty Distinguished Professor of Clinical Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He is also director of geriatrics for the NewYork-Presbyterian Healthcare System and Paul Beeson Physician Faculty Scholar from the American Federation for Aging Research through funding from the John A. Hartford Foundation.

Research by Dr. Lachs has identified such repercussions of elder abuse and neglect as overwhelming feelings of fear, isolation and anger, as well as depression, and links to decreased longevity.


'/>"/>

Contact: Jonathan Weil
jweil@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
2. $50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center
3. NewYork-Presbyterian/Weill Cornell creates world-class cancer center
4. Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis
5. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
6. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
7. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
8. By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis
9. Healthy restaurants help make us fat, says a new Cornell study
10. Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards
11. AACR CEO receives Distinguished Public Service Award
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 1ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 2ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 3ERKs got rhythm 3A Protein that controls cell growth found to cycle in and out of cell nucleus 10934 4Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 1Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 2Tepnel Pharmaceutical Services to Offer DNA Genotek 26apos 3Bs Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 15012 3Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 1Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 2Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe Finds Frost 26amp 3B Sullivan 62334 3
Other Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 2Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 3Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 5Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 6Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 7Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 8Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 9